-
Merck's Ebola Vaccine Showed 84% Effectiveness During Large Outbreak In Africa
Thursday, August 22, 2024 - 9:40am | 471Merck & Co Inc’s (NYSE:MRK) rVSV-ZEBOV vaccine is the only WHO-prequalified vaccine endorsed by the Strategic Advisory Group of Experts on Immunization for use in Ebola outbreaks caused by the Zaire ebolavirus. The FDA approved the vaccine for adults in December 2019 and for use in...
-
Stormy Conditions At Burning Man Festival Raise Health Risks Beyond Ebola Worries
Monday, September 4, 2023 - 5:15am | 408Recent storm conditions leading to flooding at the Burning Man festival have raised concerns about possible health risks, despite rumors of an Ebola outbreak being debunked, Insider reported. The festival site was hit with heavy rainfall, leading to muddy conditions and stranded attendees. Social...
-
Inovio Pharma Releases Favorable Data From Booster DNA Vaccine Candidate For Ebola
Thursday, February 2, 2023 - 2:39pm | 303Inovio Pharmaceuticals Inc (NASDAQ: INO) announced results from a Phase 1b trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo. Ervebo is an FDA-approved vaccine to prevent ebola in...
-
US Sends Gilead's COVID-19 Antiviral To Safeguard Health Workers In Uganda Ebola Outbreak
Wednesday, October 19, 2022 - 7:26am | 295The U.S. sent Gilead Sciences Inc's (NASDAQ: GILD) remdesivir and Mapp Biopharmaceutical Inc's experimental Ebola antibody drug MBP134 to Uganda as a response to the Ebola outbreak. The medicines will help safeguard healthcare workers responding to an outbreak that has...
-
Looking For Ebola Virus Meds? WHO Recommends These Two Antibody Treatments
Friday, August 19, 2022 - 12:26pm | 420The World Health Organization (WHO) has published its first guideline for Ebola virus disease therapeutics, with new recommendations for using two monoclonal antibodies. Following a systematic review and meta-analysis, WHO recommended two monoclonal antibody treatments, Ebanga (...
-
Johnson & Johnson's Ebola Vaccine Built On COVID-19 Tech Shows Durable Benefit
Tuesday, September 14, 2021 - 3:41pm | 402Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (NYSE: JNJ) Ebola vaccine regimen showed a long-lasting immune response. The regimen, which uses Zabdeno (Ad26.ZEBOV) for one shot, and Mvabea (MVA-BN-Filo) for the next...
-
Fintech Focus For February 8, 2021
Sunday, February 7, 2021 - 8:25pm | 2192Quote To Start The Day: Excessive determinism is almost always the biggest enemy of stability. This seeming contradiction is behind the concept of metastability which captures the mode of market functioning in the last years. Metastability is what seems stable, but is not — a stable waiting...
-
Regeneron's Inmazeb Becomes First Ebola Treatment To Get FDA Approval
Wednesday, October 14, 2020 - 10:44pm | 395The United States Food and Drug Administration approved Regeneron Pharmaceuticals, Inc's (NASDAQ: REGN) drug Inmazeb for the treatment of Ebola in both adults and children on Wednesday. What Happened: Inmazeb is the first-ever drug approved for the treatment of the infection caused by the...
-
18 Medical Stocks To Watch Amid The Coronavirus Outbreak
Tuesday, February 25, 2020 - 4:25pm | 1250Airlines, hotels, casinos and other stocks continue to fall as fear of the coronavirus grows worldwide and all but halts activity in the virus epicenter of Wuhan, China. One sector, in particular, could profit from the outbreak. Editor's note: This list has been updated since it was...
-
Johnson & Johnson Is 'Confident' In Ability To Treat Coronavirus, But Vaccine Could Take Time
Monday, January 27, 2020 - 10:16am | 371Johnson & Johnson (NYSE: JNJ) could play a role in fighting the coronavirus, but a vaccine could take up to a year to develop. What Happened Johnson & Johnson tasked dozens of scientists across the world to work on a vaccine for the fast-spreading coronavirus and the company is "pretty...
-
What To Know About China's Protective Face Mask Market
Thursday, January 23, 2020 - 3:24pm | 347Hazard masks are already a hot commodity in China, but the novel coronavirus has heightened demand. Chinese mask manufacturers continue to blaze through orders, turning 20 million masks per day at max capacity and declining their traditional pause for Spring Festival, according to The Global Times...
-
Lakeland Industries Grabs Investor Interest With New Ebola Cases Reported
Tuesday, May 8, 2018 - 4:55pm | 340Lakeland Industries, Inc. (NASDAQ: LAKE) closed Tuesday's trading session up 7.27 percent after the World Health Organization confirmed an Ebola outbreak in the Democratic Republic of the Congo. The producer of protective clothing isn’t guaranteed a significant sales boost, according to...
-
How Altimmune Is Trying To Get Ahead Of A Potentially Fatal 'Flu Pandemic'
Friday, June 23, 2017 - 8:15am | 1260Over the next 20 to 30 years, the world will suffer a pandemic with the potential “to bring humanity to its knees,” epidemiologist Larry Brilliant, M.D., told CNN in April. He was talking about new strains of influenza found in birds across the world. Yes, it’s the flu — not...
-
Can This Leisure Group Cruise Higher? Cramer Thinks So
Thursday, June 1, 2017 - 10:37am | 405Cruise stocks have been red-hot this year, but seem to be flying under the radar. But investors should consider picking up a few of the cruise stocks, at least according to CNBC's Jim Cramer. Cramer explained during his daily "Mad Money" show that there has been a shift in sentiment...
-
Inovio Jumps After Announcing Successful Zika, MERS Vaccine Studies
Thursday, February 23, 2017 - 12:46pm | 442Inovio Pharmaceuticals, Inc. (NASDAQ: INO) said Thursday it’s observed a 100-percent antibody response in a phase I study for a Zika virus vaccine and a 92 percent antibody response in a phase I study for a MERS vaccine. The findings were presented at a Coalition for Epidemic Preparedness...